|
|
| | (S)-3-((7-((difluoromethyl)sulfonyl)-2,2-difluoro-1-hydroxy-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile Basic information |
| Product Name: | (S)-3-((7-((difluoromethyl)sulfonyl)-2,2-difluoro-1-hydroxy-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile | | Synonyms: | (S)-3-((7-((difluoromethyl)sulfonyl)-2,2-difluoro-1-hydroxy-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile;PT2399;PT 2399;PT-2399;Benzonitrile, 3-[[(1S)-7-[(difluoromethyl)sulfonyl]-2,2-difluoro-2,3-dihydro-1-hydroxy-1H-inden-4-yl]oxy]-5-fluoro-;Hypoxia-inducible factors,Inhibitor,PT2399,inhibit,HIF-PH,HIF/HIF Prolyl-Hydroxylase,HIFs,PT-2399,PT 2399;PT2339 | | CAS: | 1672662-14-4 | | MF: | C17H10F5NO4S | | MW: | 419.32 | | EINECS: | | | Product Categories: | | | Mol File: | 1672662-14-4.mol |  |
| | (S)-3-((7-((difluoromethyl)sulfonyl)-2,2-difluoro-1-hydroxy-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile Chemical Properties |
| Boiling point | 516.0±50.0 °C(Predicted) | | density | 1?+-.0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C, stored under nitrogen | | solubility | DMSO : ≥ 200 mg/mL (476.96 mM) | | pka | 11.30±0.40(Predicted) |
| | (S)-3-((7-((difluoromethyl)sulfonyl)-2,2-difluoro-1-hydroxy-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile Usage And Synthesis |
| Biological Activity | PT2399 is a potent and selective HIF-2α antagonist, which directly binds to HIF-2α PAS B domain with an IC50 of 6 nM. PT2399 displays potent antitumor activity in vivo[1][2][3].
PT2399 (compound 10f) inhibits HIF-2α with an IC50 of 6 nM[3]. PT2399 can bind directly to the HIF-2α PAS B domain, and cripple HIF-2α's ability to bind to Aryl hydrocarbon receptor nuclear translocator (ARNT)[2].PT2399 (20 μM) causes off-target toxicity because it inhibits the proliferation of HIF-2α -/- 786-O cells and other cancer cell lines with undetectable HIF-2α[2]. PT2399 (0.2-2 μM; 0-21 days) inhibits 786-O cells soft agar growth[2].PT2399 represses various HIF target genes in 786-O VHL-/- ccRCC cells, does not suppress HIF-1α-specific targets such as BNIP3[2].
PT2399 inhibits tumor cell proliferation 3.5 fold in renal cell carcinoma (RCC) bearing mice[1].PT2399 reduces tumor cell density and increases fibrosis in RCC bearing mice[1].PT2399 (100 mg/kg; oral gavage; every 12 hours) is more active than SU 11248, and inhibits tumor growth in several SU 11248-resistant tumors in RCC bearing mice [1].PT2399 directly inhibits HIF-2α causes tumor regression in preclinical models of primary and metastatic pVHL-defective ccRCC in an on-target fashion[2]. | | References | [1]. Chen W, et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature. 2016 Nov 3;539(7627):112-117.[2]. Cho H, et al. On-Target Efficacy of a HIF2α Antagonist in Preclinical Kidney Cancer Models. Nature. Nature. 2016 Nov 3;539(7627):107-111.[3]. Wehn PM, et al. Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate (S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385). J Med Chem. 2018 Nov 8;61(21):9691-9721. |
| | (S)-3-((7-((difluoromethyl)sulfonyl)-2,2-difluoro-1-hydroxy-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile Preparation Products And Raw materials |
|